These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 20212248)

  • 1. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
    Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
    J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
    Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
    Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
    Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
    Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
    Swinnen LJ; Li H; Quon A; Gascoyne R; Hong F; Ranheim EA; Habermann TM; Kahl BS; Horning SJ; Advani RH
    Br J Haematol; 2015 Jul; 170(1):56-65. PubMed ID: 25823885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
    Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
    J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
    Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
    Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
    Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
    Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy.
    Cox MC; Ambrogi V; Lanni V; Cavalieri E; Pelliccia S; Scopinaro F; Monarca B; Marchetti P; Spiriti MA
    Leuk Lymphoma; 2012 Feb; 53(2):263-9. PubMed ID: 21846184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
    González-Barca E; Canales M; Cortés M; Vidal MJ; Salar A; Oriol A; Bargay J; Bello JL; Sánchez JJ; Tomás JF; Donato E; Ferrer S; Caballero D;
    Nucl Med Commun; 2013 Oct; 34(10):946-52. PubMed ID: 23880897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
    Chihara D; Oki Y; Ine S; Kato H; Onoda H; Taji H; Kagami Y; Yamamoto K; Morishima Y
    Eur J Haematol; 2010 Jun; 84(6):493-8. PubMed ID: 20148943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of the PET-CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results.
    Cortés Romera M; Gámez Cenzano C; Caresia Aróztegui AP; Martín-Comín J; González-Barca E; Ricart Brulles Y; Palacios Abufón A; Robles Barba J; Rodríguez-Bel L; Rossi Seoane S; Fernández de Sevilla A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):135-41. PubMed ID: 21944191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of
    Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.